Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC)

MLA

Othon Iliopoulos, et al. “Phase 1 Study of CB-839, a Small Molecule Inhibitor of Glutaminase (GLS), Alone and in Combination with Everolimus (E) in Patients (Pts) with Renal Cell Cancer (RCC).” Journal of Clinical Oncology, vol. 34, May 2016, p. 4568. EBSCOhost, https://doi.org/10.1200/jco.2016.34.15_suppl.4568.

APA

Othon Iliopoulos, Mark K. Bennett, James J. Harding, Angela DeMichele, Manish R. Patel, James W. Mier, Melinda L. Telli, Richard D. Carvajal, Alice C. Fan, Funda Meric-Bernstam, Martin H. Voss, Jeffrey R. Infante, Taofeek K. Owonikoko, Nizar M. Tannir, Rana R. McKay, Pamela N. Munster, & Keith W. Orford. (2016). Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC). Journal of Clinical Oncology, 34, 4568. https://doi.org/10.1200/jco.2016.34.15_suppl.4568

Chicago

Othon Iliopoulos, Mark K. Bennett, James J. Harding, Angela DeMichele, Manish R. Patel, James W. Mier, Melinda L. Telli, et al. 2016. “Phase 1 Study of CB-839, a Small Molecule Inhibitor of Glutaminase (GLS), Alone and in Combination with Everolimus (E) in Patients (Pts) with Renal Cell Cancer (RCC).” Journal of Clinical Oncology 34 (May): 4568. doi:10.1200/jco.2016.34.15_suppl.4568.